Erythrocyte deformability and white blood cell count are associated with aspirin resistance in high-risk vascular patients

被引:0
|
作者
Mannini, Lucia [1 ]
Marcucci, Rossella [1 ]
Paniccia, Rita [1 ]
Antonucci, Emilia [1 ]
Giglioli, Cristina [1 ]
Valente, Serafina [1 ]
Gori, Anna Maria [1 ]
Prisco, Domenico [1 ]
Gensini, Gian Franco [1 ]
Abbate, Rosanna [1 ]
机构
[1] Univ Florence, Dept Med & Surg Crit Care, Ctr Thrombosis, Azienda Osped Univ Careggi, I-50134 Florence, Italy
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recently the phenomenon of aspirin resistance has been object of several studies, but no data are available on the possible role of the haemorheologic parameters in affecting platelet function and resistance to antiplatelet agents. Aim of our study was to evaluate platelet function and haemorheology in patients with acute coronary syndromes (ACS), receiving double antiplatelet therapy with aspirin and clopidogrel. The study population included 301 (231M/70F; age: 66 +/- 13 yrs) consecutive adult patients admitted to the Coronary Care Unit of the Azienda Ospedaliero-Universitaria Careggi, with diagnosis of acute myocardial infarction or unstable angina. We assessed: whole blood viscosity (WBV) at shear rates of 0.512 s(-1) and 94.5 s(-1), plasma viscosity (PLV) at 94.5 s(-1) shear rate, erythrocyte deformability index (DI) and PFA-100 closure times with ADP (PFA/ADP) and epinephrine (PFA/EPI). We considered any PFA-100-EPI result < 203 sec (95th percentile of control distribution) to be indicative of aspirin resistance. 104/301 patients (34.5%) had PFA/EPI CTs in the reference range (group 1) whereas the remaining had values higher than 203 sec (group 2). WBV at 94.5 sec (-1) s.r. was similar in group 1 and 2 (WBV: 4.43 +/- 0.25 vs 4.45 +/- 0.61 mPa center dot sec, respectively). PLV and WBV at 0.512 sec (-1) s.r. were slightly higher, but not significantly, in group 1 than in group 2 (PLV: 1.47 +/- 0.13 vs 1.44 +/- 0.15 mPa center dot sec; p=0.08 and WBV: 23.37 +/- 4.6 vs 22.54 +/- 3.90 mPa center dot sec; p=0.07). DI was significantly lower in group 1 with respect to group 2 (4.05 +/- 2.93 vs 5.71 +/- 3.30, p < 0.0001). White blood count (WBC) was significantly higher in group 1 than in group 2 (11464 +/- 3504 vs 7867 +/- 2162, p < 0.0001). In conclusion, these results demonstrate that in patients with acute coronary syndromes the antiaggregant effect of aspirin is modulated not only by the direct action on platelets, but also by erythrocyte deformability and white blood cell count.
引用
收藏
页码:175 / 181
页数:7
相关论文
共 50 条
  • [41] Ticagrelor with or without Aspirin in High-Risk Patients after PCI
    Mehran, R.
    Baber, U.
    Sharma, S. K.
    Cohen, D. J.
    Angiolillo, D. J.
    Briguori, C.
    Cha, J. Y.
    Collier, T.
    Dangas, G.
    Dudek, D.
    Dzavik, V.
    Escaned, J.
    Gil, R.
    Gurbel, P.
    Hamm, C. W.
    Henry, T.
    Huber, K.
    Kastrati, A.
    Kaul, U.
    Kornowski, R.
    Krucoff, M.
    Kunadian, V.
    Marx, S. O.
    Mehta, S. R.
    Moliterno, D.
    Ohman, E. M.
    Oldroyd, K.
    Sardella, G.
    Sartori, S.
    Shlofmitz, R.
    Steg, P. G.
    Weisz, G.
    Witzenbichler, B.
    Han, Y.
    Pocock, S.
    Gibson, C. M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21): : 2032 - 2042
  • [42] Predictors of High On-Aspirin Platelet Reactivity in High-Risk Vascular Patients Treated With Single or Dual Antiplatelet Therapy
    Amsallem, Myriam
    Manzo-Silberman, Stephane
    Dillinger, Jean-Guillaume
    Sideris, Georgios
    Voicu, Sebastian
    Sollier, Claire Bal Dit
    Drouet, Ludovic
    Henry, Patrick
    AMERICAN JOURNAL OF CARDIOLOGY, 2015, 115 (09): : 1305 - 1310
  • [43] CLOPIDOGREL AND ASPIRIN VERSUS ASPIRIN ALONE IN HIGH-RISK PATIENTS WITH ESTABLISHED VASCULAR DISEASE; A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
    Kamireddy, Swapna
    Sabatine, Marc S.
    Bhatt, Deepak L.
    Steinhubl, Steven R.
    Boden, William E.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (10)
  • [44] White blood cell count measured prior to cancer development is associated with future risk of venous thromboembolism in cancer patients' the Tromso study
    Jensvoll, Hilde
    Blix, Kristine
    Braekkan, Sigrid
    Hansen, John-Bjarne
    THROMBOSIS RESEARCH, 2012, 130 : S198 - S198
  • [45] LOW-DOSE ASPIRIN LOWERS RISK OF PREECLAMPSIA IN HIGH-RISK PATIENTS
    Rosenberg, Karen
    AMERICAN JOURNAL OF NURSING, 2015, 115 (01) : 57 - 57
  • [46] Cruciate Fenestration in Ventricular Septal Defect Patch for High-Risk Patients With High Pulmonary Vascular Resistance
    Sridhar, Anuradha
    Sahayaraj, Anto
    Lakshmi, Nithya
    Farzana, Farida
    Subramanyan, Raghavan
    Pezzella, A. Thomas
    Cherian, Kotturathu Mammen
    WORLD JOURNAL FOR PEDIATRIC AND CONGENITAL HEART SURGERY, 2014, 5 (03) : 494 - 496
  • [47] Impact of Adding Aspirin to Beta-Blocker and Statin in High-Risk Patients Undergoing Major Vascular Surgery
    Lau, Wei C.
    Froehlich, James B.
    Jewell, Elizabeth S.
    Montgomery, Daniel G.
    Eng, Kristina M.
    Shields, Theresa A.
    Henke, Peter K.
    Eagle, Kim A.
    ANNALS OF VASCULAR SURGERY, 2013, 27 (04) : 537 - 545
  • [48] Aspirin resistance is associated with aspirin dosage, mean platelet volume and platelet count in patients with acute coronary syndromes
    Acikel, S.
    Yildirir, A.
    Aydinalp, A.
    Bal, U.
    Kaynar, G.
    Demirtas, K.
    Ozin, B.
    Muderrisoglu, H.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 398 - 398
  • [49] Association of White Blood Cell Count and Peripheral Arterial Disease in Patients With and Without Traditional Risk Factors
    Chen, Jien-Jiun
    Lin, Lian-Yu
    Lee, Hsiu-Hao
    Lai, Lin-Ping
    Lin, Jiunn-Lee
    Huang, Juey-Jen
    Tseng, Chuen-Den
    ANGIOLOGY, 2010, 61 (04) : 382 - 387
  • [50] Obesity and laboratory aspirin resistance in high-risk pregnant women treated with low-dose aspirin
    Finneran, Matthew M.
    Gonzalez-Brown, Veronica M.
    Smith, Devin D.
    Landon, Mark B.
    Rood, Kara M.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2019, 220 (04) : 385.e1 - 385.e6